FISHKILL, N.Y., Jan. 24, 2013 /PRNewswire/ -- Nano Mask, Inc., (PINKSHEETS: NANM), a materials technology development company focused on health and wellness related markets, today announced that it has appointed Hassan Bennani , MD, to its Board of Directors.
Dr. Bennani is the co-founder and CEO of KellBenx, Incorporated, a closely held Long Island, NY based biotechnology company focused on women's healthcare, concentrating on the development of a patented breakthrough non-invasive prenatal diagnostic (NIPD) for analyzing genetic disorders and a patent pending breakthrough test to determine a woman's risk of preterm delivery.
Dr. Bennani was previously the head of business development at Lenetix, a women's health focused lab acquired by Bio-Reference Laboratories. Prior to that, Dr. Bennani was a Vice President of Sales and Marketing for Adeza Biomedical Corporation, which was acquired by Hologic.
"I am excited about joining forces with Nano Mask , which has assembled an impressive hospital textile product portfolio that can grow its sales significantly over the next few years," said Dr. Bennani, who went on to add, "I am confident that the industry contacts that I have made over the course of my career, especially in international markets, will be very receptive to Nano Mask 's products."
"Dr. Bennani's extensive experience and network make him ideally suited to help promote our products both in the United States and internationally," said Edward Suydam , President and CEO, Nano Mask Inc.
About Nano Mask , Inc.
We are a healthcare product development and distribution company providing innovative and cost effective emergency and critical care and infection control products
|SOURCE Nano Mask , Inc.|
Copyright©2012 PR Newswire.
All rights reserved